The significance of changes in thyrotropin receptor antibody and soluble intercellular adhesion molecule-1 levels in patients with thyroid-associated ophthalmopathy during intravenous methylprednisolone pulse treatment
10.3760/cma.j.issn.1000-6699.2010.10.008
- VernacularTitle:甲泼尼松龙冲击治疗甲状腺相关性眼病时TRAb和sICAM-1的变化及意义
- Author:
Ping FAN
;
Bingyin SHI
;
Hui GUO
;
Li XU
- Publication Type:Journal Article
- Keywords:
Thyroid-associated ophthalmopathy;
Thyrotropin receptor antibody;
Soluble intercellular adhesion molecule-1
- From:
Chinese Journal of Endocrinology and Metabolism
2010;26(10):859-862
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship of thyrotropin receptor antibody (TRAb) and soluble intercellular adhesion molecule-1 ( sICAM-1 ) in patients with thyroid-associated ophthalmopathy ( TAO), and the role played by TRAb and sICAM-1 in the pathogenesis of TAO. Method Twenty-three TAO patients were assigned to groups according to the clinical activity score and EUGOGO. All patients were treated with intravenous methylprednisolone pulse. The levels of serum TRAb and sICAM-1 were evaluated by a competitive radioimmunoassay and enzyme-linked immunosorbent assay respectively before treatment and by the end of each methylprednisolone pulse. Results The differernce in serum TRAb levels was associated with activity scores of TAO (P=0. 020). The change in serum sICAM-1 was associated with durations of TAO ( P = 0.015). During methylprednisolone treatment in active TAO patients, the levels of TRAb kept on decreasing gradually and markedly declined after the third methylprednisolone pulse in active TAO patients (P＜0.05). The trends of changes in serum TRAb and sICAM-1 levels were both different in active and inactive TAO patients by tendency analysis. Conclusion TRAb level was related to the activity of TAO and might serve as a significant predictor of response to methylprednisolone therapy. The negative correlation between sICAM-1 levels and duration of TAO corroborates the role played by ICAM-1 during the early stage of TAO. Higher sICAM-1 levels are not expected to be specific to TAO and may not predict a response to methylprednisolone therapy.
